Pirlindole in the Treatment of Depression
- 79 Downloads
Background: Depressive disorders are common health problems. Both preclinical and clinical studies have shown that pirlindole, a tetracyclic compound, is suitable for the management of depression; however, a systematic review is needed to accurately select randomized controlled trials (RCTs) for a meta-analysis that will provide more consistent and accurate results regarding the efficacy and tolerability of the drug.
Objectives: To evaluate the efficacy and frequency of adverse events with pirlindole in comparison with active comparators (monoamine oxidase inhibitors [MAOIs], tricyclic antidepressants, tetracyclic antidepressants, and selective serotonin reuptake inhibitors [SSRIs]) for the treatment of major depression.
Methods: Data were searched through MEDLINE (via PubMed), EMBASE, the Cochrane Central Register of Controlled Trials and a manual search through the sponsor’s available archives (1966 to 30 August 2010). The metaanalysis was performed using the Mantel-Haenszel technique and analysing data through Comprehensive Meta-Analysis software version 1.0.23. Studies were included if they were RCTs evaluating the efficacy and number of reported adverse events with pirlindole in comparison with active comparators for the treatment of major depression in adults. Placebo-controlled trials were excluded to minimize study heterogeneity.
Results: This systematic review included ten published articles and one nonpublished report corresponding to a total of 13 clinical trials in the adult population. Two RCTs were excluded from the meta-analysis because the comparator was placebo. Two more studies were excluded, one because randomization could not be confirmed and the other because it described follow-up data on patients from a study that had already been included in the meta-analysis. Therefore, only nine RCTs were included in the meta-analysis. No differences were found between pirlindole and its active comparators with regard to the percentage of patients whose clinical condition improved by 50% according to the Hamilton Depression Rating Scale (HDRS) [odds ratio (OR) 1.52; 95% confidence interval [CI] 0.92, 2.51; p = 0.11] and Hamilton Anxiety Rating Scale (HARS) [OR 1.15; 95% CI 0.69, 1.90; p = 0.59]. With regard to the improvements in HDRS and HARS, the results were favourable for patients treated with pirlindole (depression: absolute value 0.18; 95% CI −0.01, 0.37; p = 0.06; anxiety: absolute value 0.26; 95% CI 0.03, 0.48; p = 0.03).
Conclusion: This systematic review and meta-analysis showed that all RCTs included reported efficacy outcomes for pirlindole comparable to those of its comparators, and that pirlindole was significantly better in terms of reducing anxiety symptoms. However, the analysis of these results should take into account the quality of the original included articles, which had a mean Jadad trial quality score of 3.7 (out of 5). Therefore, further clinical trials should be conducted to evaluate the benefits of pirlindole.
KeywordsBipolar Disorder Fluoxetine Tyramine Active Comparator Moclobemide
Grupo Tecnimede markets pirlindole in Portugal and funded the conduct of this meta-analysis and the preparation of this article.
Ana Macedo, MD, PhD, and Eva Leiria, MS, work as scientific advisers at KeyPoint, Consultoria Científica, Lda. Augusto Filipe, MD, is an employee of Grupo Tecnimede and reviewed the final manuscript. The authors have no other conflicts of interest that are directly relevant to the content of this meta-analysis.
The authors wish to thank Ana Maria Tomé, PharmD, and Inês Moital for assistance in the revision of the article and Liliana Coelho for assistance in the management of the manuscript submission and bibliographic research.
- 1.WHO. Mental health [online]. Available from URL: http://www.who.int/mental_health/management/depression/ definition/en/ [Accessed 2010 May 17]Google Scholar
- 5.Möller H-J, Müller WE, Volz HP. Psychopharmakotherapie: ein Leitfaden für Klinik und Praxis. 2nd ed. Stuttgart Berlin Köln: Kohlhammer, 2000Google Scholar
- 6.Patkar AA, Pae C, Masand P. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006; 5: 363–75Google Scholar
- 16.De Wilde J, Mertens C, Dorpe JV, et al. Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmacol 1997; 12: 41–6Google Scholar
- 17.Schäpperle O, Eckmann F, Immich H. A double-blind comparison of pirlindole with amitriptyline and imipramine. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 297–302Google Scholar
- 19.Silverstone T. Introduction to a new generation of antidepressant drugs: pirlindole. Psicopatologia 1987; 7: 432–6Google Scholar
- 20.Lehmann E, Kinzler E, Stuckmann A, et al. A double-blind comparative study on the use of 225mg pirlindole and 150mg desipramine in the treatment of depressive inpatients. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 321–7Google Scholar
- 21.Renfordt E. A comparison of pirlindole and amitriptyline in a double-blind controlled study. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 311–7Google Scholar
- 22.Blaha L. A double-blind comparative study of pirlindole and amitriptyline in thirty depressive patients. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 303–9Google Scholar
- 23.Saletu B, Grünberger J, Rajna P, et al. Examining pharmaco EEG-based predictions about the antidepressant action of pirlindole by double blind clinical trials. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 291–6Google Scholar
- 24.Pöldinger W. Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline. In: Pichot P, Berner P, Wolf R, et al, editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 3: 283–9Google Scholar
- 26.Geerts S, Vandekerckhovev K, Bruhwyler J, et al. Pirlindole versus fluoxetine in the treatment of major depression: a controlled double-blind medium-term study. Prior Velho: Grupo Tecnimede, 2000. (Data on file)Google Scholar
- 27.Zapletálek M, Libiger J, Kaspárkova I, et al. Pyrazidol in the treatment of endogenous depression: a controlled study. Activ Nerv Sup 1981; 23: 200–2Google Scholar
- 29.Diversity and heterogeneity [online]. Available from URL: http://www.cochrane-net.org/openlearning/HTML/ mod13-4.htm [Accessed 2003 Nov 18]Google Scholar